Organizational measures for early detection of pharyngeal mycosis using questionnaires

Objective. Analysis of organizational measures for early detection of pharyngeal mycosis in patients with respiratory diseases by validating original questionnaires.

Materials and methods. In a prospective study for early detection of pharyngeal mycosis in patients with respiratory diseases, 127 children (2-17 years old) participated in the pulmonology department of the “Gomel Regional Clinical Hospital” from October to December 2018. Questionnaires using original tools were completed by the children’s legal representatives. The diagnosis of pharyngeal mycosis was verified comprehensively: clinical examination (pharyngoscopy), microscopy (KOH, Gram), mycological culture (titer ≥10⁴ CFU/ml). An analysis of organizational measures for early detection of pharyngeal mycosis in patients with respiratory diseases was performed by validating the authors’ questionnaires. Statistical analysis was performed in R environment (version 4.5.0) using packages: rstatix (statistical testing), ggstatsplot and ggplot2 (visualization), pROC (ROC analysis), and dplyr (data manipulation).

Results. The validated express questionnaire for patients with pharyngeal mycosis (EQPM) associated with respiratory diseases (≥6 points: PPV=81%, NPV=77,4%, AUC=0.684, point-biserial correlation r=0.816, p<0.001), and the questionnaire for anxiety in pharyngeal mycosis (QAPM) (98% vs 8% of disorders with/without pharyngeal mycosis, AUC=0.982, point-biserial correlation r=0.963, p<0.001) revealed a strong association of pharyngeal mycosis with somatic symptoms and psychosomatic disorders, justifying their use for early detection of pharyngeal mycosis and the need for an interdisciplinary approach.

Conclusion. Implementation of the EQPM and QAPM into clinical practice allows optimizing the early diagnosis of pharyngeal mycosis in patients with respiratory diseases, timely initiate etiotropic therapy, assess concomitant psychosomatic symptoms, and personalize treatment improving control of the basic disease and patients’ quality of life.

1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-e50. DOI: https://doi.org/10.1093/cid/civ933

2. Hoenigl M, Salmanton-García J, Cornely OA, Koehler P, Lass-Flörl C, Prattes J, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guideline for the diagnosis and management of rare invasive yeast infections 2024. Clin Microbiol Infect. 2024 Mar;30 Suppl 2:S1-S45. DOI: https://doi.org/10.1016/j.cmi.2024.01.007

3. Patil S, Majumdar S, Rao MA. Oropharyngeal Candidosis in HIV-Infected Patients—An Update. Front Microbiol. 2018 May 7;9:980. DOI: https://doi.org/10.3389/fmicb.2018.00980

4. Scully C. Oral and Maxillofacial Medicine: The Basis of Diagnosis and Treatment. 3rd ed. Edinburgh: Churchill Livingstone Elsevier; 2013. 456 p.

5. Kim SH, Park JY, Lee MJ. The Impact of Chronic Oropharyngeal Candidiasis on Quality of Life and Treatment Outcomes in Patients with Asthma on Inhaled Corticosteroids. J Asthma. 2023 Jan;60(1):123-131. DOI: https://doi.org/10.1080/02770903.2022.2036765

6. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-276. DOI: https://doi.org/10.1007/s10096-007-0270-z

7. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-370. DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x

8. Starodubtseva MN, Kovalev AA, Kulikovich DB, Kuznetsov BK. Methodological problems of teaching the scientific approach to the analysis of clinical data in the study of the course of biomedical statistics at a medical university. In: Stoma IO, edit. Сurrent issues in medicine: compendium of scientific papers from the republican research-to-practice conference with international involvement; 2022 Nov 10; Gomel, Belarus. In 3 vol. Vol.1. Gomel: GomGMU; 2022. p. 87-90. (Russ.).

9. Arendrup MC, Cornely OA, Mouton AJMM, Lagrou K, Hamal P, Manuel O, et al. ECMM/ISHAM recommendations for clinical management of Candida auris outbreaks. Lancet Infect Dis. 2023 Jun;23(6):e218-e224. DOI: https://doi.org/10.1016/S1473-3099(23)00085-8

10. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. ERS guidelines on the use of inhaled corticosteroids in adult chronic obstructive pulmonary disease. Eur Respir J. 2022 Oct;60(4):2103181. DOI: https://doi.org/10.1183/13993003.03181-2021

11. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016 Jan;47(1):45-68. DOI: https://doi.org/10.1183/13993003.00583-2015

12. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. New Antifungal Strategies: Drug Combination and Co-delivery. Front Cell Infect Microbiol. 2021 May 13;11:672006. DOI: https://doi.org/10.3389/fcimb.2021.672006

13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. DOI: https://doi.org/10.1111/j.2044-8341.1959.tb00467.x

14. Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J Fungi (Basel). 2017 Dec;3(4):57. DOI: https://doi.org/10.3390/jof3040057

15. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. DOI: https://doi.org/10.1016/S0140-6736(20)30925-9

16. Katsoulis O, Pitts OR, Singanayagam A. The airway mycobiome and interactions with immunity in health and chronic lung disease. Oxford Open Immunol. 2024;5(1):iqae009. DOI: https://doi.org/10.1093/oxfimm/iqae009

17. Stoma IO. Airway Microbiome: textbook. Moscow: GEOTAR-Media; 2023. 101 p. (Russ.).

18. Stoma IO. Microbiome in Medicine: clinical guidelines. Moscow: GEOTAR-Media; 2020. 319 p. (Russ.).

19. Mezheinikova MO, Bulanova AD. Pharyngeal Microbiome. In: Rubnikovich SP, edit. Fundamental science in contemporary medicine – 2023: proceedings of the research and practice conference for students and young scientists; February-March 2023; Minsk. Minsk: BGMU; 2023. p. 92-94. (Russ.).

20. Winter G, Hart RA, Charlesworth RPG, Sharpley CF. Gut microbiome and depression: what we know and what we need to know. Rev Neurosci. 2018 Aug 28;29(6):629-643. DOI: https://doi.org/10.1515/revneuro-2017-0072

21. Yang YL, Chu WL, Lin CC, Tseng YJ, Wu TSJ, Liu WL. Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review. Front Pharmacol. 2021;12:697330. DOI: https://doi.org/10.3389/fphar.2021.697330

22. Mezheinikova MO, Chelebieva NP, Novik AV. Neuropsychological Status of Patients with Pharyngeal Mycosis. Otorhinolaryngology. Eastern Europe. 2023;13(2 Electron. Adj.):80-44. (Russ.). [access date: 25 May 2025]. Available from: https://recipe.by/wp-content/uploads/woocommerce_uploads/2023/06/Tezisy_Prilozhenie-k-Otorino_2-2023.pdf